HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Erythromycin Gluceptate

HCID 16051953
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
23067-13-2
Standard SMILES
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
InChIKey
ZXBDZLHAHGPXIG-VTXLJDRKSA-N
Molecular formula
C44H81NO21
Average molar mass
960.1 g/mol
Monoisotopic mass
959.53010859

Overview

Erythromycin is a macrolide antibiotic produced by Streptomyces erythreus. It inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits; binding inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.

Names & identifiers

Preferred name
Erythromycin Gluceptate
IUPAC
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2R,3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acid
English name
ERYTHROMYCIN GLUCEPTATE (200 MG)
Molecular formula
C37H67NO13.C7H14O8
Molecular weight
960.11

Names & synonyms

Erythromycin glucoheptonateERYTHROMYCIN GLUCEPTATE23067-13-2Ilotycin gluceptate2AY21R0U64Erythromycin gluceptate (USP)Erythromycin Gluceptate [USP]DTXSID001027300RefChem:58716DTXCID501511568245-407-6Erythromycin glucoheptonate (1:1) (salt)
Show more names
ilotycingluceptateerythrohycingluceptateerythromycingluceptateerythromycin,glucoheptonate(1:1)ERYTHROMYCIN GLUCEPTATE (200 MG)Erythromycin Gluceptate (1246000)erythromycin,glucoheptonicacidsalterythromycin,monoglucoheptonate(salt)glucoheptonicacid,compd.witherythromycin(1:1)Erythromycin Gluceptate (200 mg) (DISCONTINUED)
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2R,3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acidErythrohycin gluceptateIlotycin glucoheptonateUNII-2AY21R0U64EINECS 245-407-6Erythromycin, glucoheptonic acid saltIlotycin gluceptate (TN)SCHEMBL152260

Properties

Computed structural propertiesFilling in

Topological polar surface area
353 Ų
Hydrogen bond donors
12
Hydrogen bond acceptors
22
Rotatable bonds
13
Heavy atoms
66
Formal charge
0
Complexity
1,380

Experimental & physicochemical properties

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physicochemical properties

Melting point
95 · 95-140°
solubility
DMSO (Sparingly), Methanol (Slightly)
form
Solid
color
White to Off-White
Stability
Hygroscopic
FDA UNII
2 AY21R0U64 · 2AY21R0U64
HS Code
2941500000 · 2941500000

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS ClassificationNot Classified

Hazard information

Regulatory InformationD-glycero-D-gulo-Heptonic acid, compd. with erythromycin (1:1): Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesNot Classified

Toxicology

Exposure RoutesOrally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Topical application of the ophthalmic ointment to the eye may result in absorption into the cornea and aqueous humor.
Toxicity Summary · 1 item

Erythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the “P” or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the “A” or acceptor site to the “P” or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.

Signs and SymptomsSymptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting.
Carcinogen Classification

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 1 item

Hepatic. Extensively metabolized - after oral administration, less than 5% of the administered dose can be recovered in the active form in the urine. Erythromycin is partially metabolized by CYP3A4 resulting in numerous drug interactions. Half Life: 0.8 - 3 hours

Uses & manufacturing

Uses · 1 item

For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to <i>Corynebacterium diphtheriae</i>, in the treatment of infections due to <i>Corynebacterium minutissimum</i>, intestinal amebiasis caused by <i>Entamoeba histolytica</i>, acute pelvic inflammatory disease caused by <i>Neisseria gonorrhoeae</i>, skin and soft tissue infections of mild to moderate severity caused by <i>Streptococcus pyogenes</i> and <i>Staphylococcus aureus</i>, primary syphilis caused by <i>Treponema pallidum</i>, infections caused by <i>Chlamydia trachomatis</i>, nongonococcal urethritis caused by <i>Ureaplasma urealyticum</i>, and Legionnaires' disease caused by <i>Legionella pneumophila</i>.

Applications

UsesAntibacterial.

UsesErythromycin Glucoheptonate is a derivative of Erythromycin (E649950), an antibiotic.

Upstream & downstream products

Upstream raw materials

ErythromycinD-Glucoheptonic acid γ-lactone

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
23067-13-2
PubChem CID
16051953
DTXSID
DTXSID001027300
ChEMBL
CHEMBL3545060
UNII
2AY21R0U64
EC Number
245-407-6
No indication of carcinogenicity to humans (not listed by IARC).

Safety data

hs_code
2941500000